MC
GLMD icon

Menta Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Menta Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-24
Closed -$239K – 546
2018
Q4 		$239K Sell
24
-10
-29% -$140K 0.09% 371
2018
Q3 		$668K Buy
+34
New +$637K 0.23% 123
2017
Q1 		– Sell
-18
Closed -$93K – 873
2016
Q4 		$93K Buy
18
+8
+80% +$42.3K 0.01% 832
2016
Q3 		$65K Sell
10
-3
-23% -$18.1K 0.01% 791
2016
Q2 		$81K Buy
13
+1
+8% +$7.56K 0.01% 829
2016
Q1 		$86K Hold
12
– – 0.01% 876
2015
Q4 		$129K Buy
12
+1
+9% +$12.8K 0.02% 808
2015
Q3 		$117K Buy
11
+1
+10% +$13.2K 0.02% 671
2015
Q2 		$145K Hold
10
– – 0.02% 618
2015
Q1 		$130K Buy
+10
New +$120K 0.02% 653

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Menta Capital's GLMD Position: Q1 2019 in Review

Menta Capital sold out of Galmed Pharmaceuticals (GLMD) in Q1 2019, closing a stake of 24 shares — an estimated $239K sold.

Menta Capital first reported a position in GLMD in Q1 2015 and held it in 10 quarters. The position peaked at $668K in Q3 2018. 29 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

  • Menta Capital reported no remaining Galmed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Menta Capital sold 24 Galmed Pharmaceuticals shares in Q1 2019, an estimated $239K.
  • Menta Capital first reported a position in Galmed Pharmaceuticals in Q1 2015 and held it in 10 quarters.
  • Menta Capital's Galmed Pharmaceuticals position peaked at $668K in Q3 2018.
  • 29 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on Menta Capital's 13F filing for Q1 2019, filed 1 May 2019.